Clinical trial

Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer

NCT05751941

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2023-02-14

PhasePHASE2

Study timeline

Study start (actual)2023-02-14Date precision: day

Registry last updated2026-09-15

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Prostate Cancerunresolved

Metastatic Prostate Cancerunresolved

Interventions

AbirateroneDRUG · verified · RxNorm: abiraterone

EnzalutamideDRUG · verified · RxNorm: enzalutamide

ApalutamideDRUG · verified · RxNorm: apalutamide

Sipuleucel-TDRUG · verified · RxNorm: sipuleucel-T

Sponsors & collaborators

H. Lee Moffitt Cancer Center and Research Institutelead sponsor

Dendreoncollaborator

Mapped research locations

ColumbusOhio, United States1 TampaFlorida, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05751941 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.